Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study.: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study. (NCT01056822), a randomized phase 4 study. The primary outcome is Number of Participants Achieving at Least Two Mycophenolic Acid (MPA) Dose Steps Higher and Reducing Tacrolimus Dose at the End of the Study.

2. Clinical Question

3. Trial Design

This was a Phase 4, randomized, parallel-group, open-label study. The registry record lists enrollment of 89 and a completed status. The recorded start is 2010-05, and the primary completion is 2013-04. Novartis Pharmaceuticals is named as the sponsor. The study title identifies the comparison as mycophenolate sodium (MPS) versus mycophenolate mofetil (MMF), with the stated aim of assessing dose optimization and tacrolimus dose reduction.

Random allocation means that assignment to the study arms was intended to be determined by chance. That design can support a causal comparison when allocation, follow-up, outcome measurement, and analysis are appropriately conducted, but the registry information does not give the allocation sequence, concealment procedures, or detailed analysis methods. The parallel model means participants were assigned to one arm rather than crossing between the two treatments. Masking was listed as none, so this was an open-label comparison.

The primary endpoint was assessed at 12 months from baseline and counts participants meeting a combined dose criterion. The record also lists 24 outcome measures, including renal function measures, gastrointestinal symptom scores, a quality-of-life score, and analyses of symptom-score changes stratified by UGT1A9 single-nucleotide polymorphism status. The registry record does not provide numerical findings for these outcomes in the information available for this analysis. It lists no outcome analyses.

The primary-outcome population is described as an intention-to-treat population with requirements for consent, receipt of at least one dose, and usable baseline and post-baseline data. This description appears truncated in the registry record. Further details about participant flow, arm-specific enrollment, protocol deviations, dose administration, follow-up completeness, and the conduct of the trial are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Intention-to-treat (ITT) population included all randomised patients who gave signed informed consent and received at least one dose of study medicinal product and had at least one baseline visit and one post-baseline visit (containing data to allow primary endpoint to be calculated, i.e. dose of MPA or MMF and Tacrolimus).

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: The intention-to-treat (ITT) population consisted of all randomised patients who gave signed informed consent and received at least one dose of the study medicinal product and have at least one baseline visit and one post-baseline visit (containing data to allow the primary endpoint to be calculated) Standard Deviation

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants Achieving at Least Two Mycophenolic Acid (MPA) Dose Steps Higher and Reducing Tacrolimus Dose at the End of the Study, measured over at 12 months from baseline.

The primary endpoint counts participants who, at 12 months from baseline, achieved at least two mycophenolic acid (MPA) dose steps higher and reduced their tacrolimus dose. It is a count of participants satisfying both parts of the stated criterion, rather than a continuous measurement of dose or a measure of the average change in dose. The registry record describes the endpoint population as intention-to-treat, subject to its stated requirements for consent, treatment receipt, and baseline and post-baseline data.

As a general statistical point, a combined endpoint can represent whether a treatment strategy reaches several linked goals in the same participant. Here, the two conditions concern MPA dose escalation and tacrolimus dose reduction. Counting participants who meet both makes the endpoint directly aligned with that joint objective as worded in the trial title. It does not, by itself, show the separate distribution of each dose change, the size of the changes, or whether a participant met one condition but not the other. Those details are not reported in the registry record.

The primary endpoint is named, but outcome counts by arm and a statistical comparison are not reported in the registry record. Therefore the observed frequency of meeting the criterion, and the precision of any between-arm contrast, cannot be described from the record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Randomized allocation is a design method for making treatment groups comparable, on average, with respect to both measured and unmeasured characteristics. That benefit depends on proper implementation and does not guarantee that the realized groups are identical. The registry record identifies the study as randomized, but details of sequence generation, allocation concealment, stratification, and any restrictions on assignment are not reported in the registry record.

What does the parallel, open-label design imply?

In a parallel-group trial, each participant is assigned to one treatment arm and followed within that arm. The recorded model is parallel, and the study is described as open-label, with masking listed as none. As a general matter, lack of masking can affect behavior, co-interventions, reporting of subjective symptoms, and assessment of outcomes when those processes are influenced by knowledge of assignment. The primary endpoint includes dose changes, and the registry record does not provide enough detail to assess how dose decisions were made or whether the outcome assessment was independent of treatment assignment. This is a methodological consideration, not evidence that bias occurred.

How should the primary endpoint be analyzed?

The outcome is a count of participants meeting a yes-or-no criterion. For a two-arm comparison, standard approaches can estimate arm-specific event frequencies and a contrast between arms, with an interval describing uncertainty. General choices for the contrast include differences or ratios of event frequencies, but the registry record does not report which measure or statistical model was planned or used. No comparative estimate or confidence interval is reported, so no particular method can be attributed to this study.

The endpoint combines two conditions: at least two higher MPA dose steps and a reduced tacrolimus dose. A participant must satisfy both to count as meeting the stated endpoint. General interpretation of a combined criterion requires attention to its components, since a single overall count does not reveal how often each component occurred separately. Component-specific results and definitions of a dose step are not reported in the registry record.

What does uncertainty mean?

In general, a confidence interval expresses the range of effect estimates reasonably compatible with the observed data under the method's assumptions. It communicates precision as well as the estimated direction and size of an effect. A p-value, when used, measures how incompatible the data are with a specified null model; it does not measure the probability that a treatment is effective or that the null hypothesis is true. The registry record does not report a confidence interval or a p-value for the primary endpoint, and no numerical inference can be reconstructed from the endpoint definition alone.

The sample-size assumptions describe an illustrative planning calculation based on the observed effect, using a two-sided significance level of 0.05, equal allocation between arms, and a normal approximation. The target effect is specified as a fraction of the observed effect. Such calculations are planning illustrations, not observed power and not proof that a study was adequately powered. Their interpretation depends on the estimated effect used, the selected fraction, the assumed design, and the statistical approximation. The assumptions do not establish that these were the trial's own design criteria; the registry record does not report the trial's sample-size justification. The actual planning outputs and the underlying observed primary effect are not reported in the registry record.

Because the primary outcome has several categories or time points, it was not reduced to one comparison for the analysis information available. This means a single recalculated, unadjusted comparison is not available to interpret. In general, a recalculation from summary data would be a separate, unadjusted calculation and would not replace a sponsor's own analysis if the two differed. No recalculated primary comparison or sponsor analysis is reported in the registry record.

Why can over-dispersion matter?

Over-dispersion is a general issue for count outcomes when variability exceeds what a chosen count model assumes. If present, standard errors based on the narrower variance assumption can be too small, leading to confidence intervals that are too narrow and tests that are too optimistic. The primary outcome is a count of participants meeting a binary criterion, not a repeated event count for each participant. The registry record does not identify a count model or report an assessment of over-dispersion, so there is no basis to say it was relevant to, or handled in, the primary analysis.

For the secondary outcomes, different measurement scales and repeated time points can call for different analytic methods. Renal function measures, symptom scores, quality-of-life scores, and genotype-stratified changes are not interchangeable outcomes. The registry record lists these outcome topics but does not report their models, covariates, treatment contrasts, or numerical findings. Consequently, no specific model choice or model assumption can be evaluated.

10. Multiplicity, Missing Data and Analysis Populations

The registry record lists 24 outcome measures and no analyses. Multiple outcomes can create multiplicity: when many hypotheses are examined, the chance of at least one apparently notable result can increase if each is assessed without an adjustment or a prespecified hierarchy. As a general matter, trial reports may address this through a designated primary endpoint, a testing sequence, or an adjustment to statistical inference. The registry record does not report a multiplicity strategy, such as a testing hierarchy or adjustment method. It is therefore not possible to determine how the listed secondary outcomes were intended to relate to confirmatory conclusions.

The primary endpoint is specified at 12 months from baseline. The listed secondary outcomes span different measures and include several gastrointestinal symptom assessments and genotype-stratified symptom-score changes at named visits. The record does not explain whether these were exploratory or confirmatory, whether any were co-primary, or how time points were selected for inference. Those details are not reported in the registry record.

The primary population description includes randomized participants who gave signed informed consent, received at least one dose, and had baseline and post-baseline data permitting calculation of the endpoint. This is not enough information to establish precisely how all randomized participants were handled. Although the population is called intention-to-treat, the stated requirements exclude participants without the specified treatment exposure or usable outcome data. The registry record does not report how many participants were excluded from this population, how missing primary outcome data were handled, or whether sensitivity analyses were conducted.

Missing-data methods matter because an analysis based only on participants with observed outcomes may be biased if missingness is related to treatment assignment or outcome status. This is a general concern, not a finding about this trial. The reasons for missing data, follow-up completeness, imputation methods, and treatment of protocol deviations are not reported in the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: acute coronary syndrome (2.5%), graft infection (2.5%), human polyomavirus infection (2.5%), urinary tract infection (2.5%), renal cell carcinoma (2.5%).

The safety record lists two groups: Micofenolato Sodium, with 46 participants at risk for serious adverse events and 2 affected, and 40 at risk for other adverse events with 13 affected; and Micofenolato Mofetilo, with 40 at risk for serious adverse events and 4 affected, and 40 at risk for other adverse events with 10 affected. These are reported counts with their listed group denominators. They should not be treated as a complete safety comparison or interpreted as adjusted estimates.

The record also lists serious adverse event terms with percentages: Acute coronary syndrome, 2.5%; Graft infection, 2.5%; Human polyomavirus infection, 2.5%; Urinary tract infection, 2.5%; Renal cell carcinoma, 2.5%; and Diarrhoea, 2.2%. The percentages are reported as listed; their precise denominators and any overlap among events are not reported in the registry record. The terms do not establish whether events were caused by treatment.

Deaths are not reported in the registry record. Timing, severity grading, event adjudication, and treatment relatedness are also not reported. Safety counts can describe what was recorded, but without fuller definitions and follow-up details they do not alone quantify comparative risk.

12. What the Result Does, and Does Not, Mean

The central result needed to answer the trial's stated primary question is not reported in the registry record. The record defines a 12-month endpoint based on achieving at least two higher MPA dose steps while reducing tacrolimus dose, but gives no arm-specific counts or comparative estimate. Consequently, it cannot show whether one arm had more participants meeting the criterion, by how much the groups differed, or how uncertain such a difference would be.

This absence is not equivalent to a finding of no difference. It is also not evidence that the intended dose strategy succeeded or failed. Without the outcome data and analysis, the primary question remains unanswered by the information in the registry record. The same caution applies to the listed secondary outcomes: their names describe planned measurements, not results.

Even if a difference in the combined endpoint were reported, interpretation would require attention to the endpoint components, participant flow, analysis population, and uncertainty. A combined count would not alone indicate the size of dose changes or how each component contributed. Further details about dose steps, dose-adjustment procedures, and the handling of participants without evaluable outcomes are not reported in the registry record.

The serious and other adverse event counts are descriptive safety information. They do not by themselves establish a causal relationship, and the listed event terms do not provide a full comparison of risks. The registry record does not report event relatedness, a statistical safety analysis, or deaths. Accordingly, the posted safety information should be interpreted narrowly as recorded counts and terms.

In general, randomized design can strengthen comparative interpretation, but the value of that design depends on complete outcome reporting and transparent analysis. Here, the design is described, while the primary comparison and analysis details are not reported in the registry record. Statistical interpretation should therefore remain limited to the trial question and the information explicitly recorded.

13. Why This Trial Matters Statistically

This study is statistically notable for asking a joint treatment-strategy question rather than measuring only a single dose in isolation. Its primary endpoint combines an increase in MPA dose steps with a reduction in tacrolimus dose and counts participants achieving both at 12 months. That framing makes the endpoint a measure of whether the paired objective was met, while leaving the separate contributions of each component important for interpretation.

The randomized parallel design provides a framework for comparing MPS with MMF. The open-label status is also relevant: as a general methodological matter, knowledge of assigned treatment can influence decisions and assessments, especially when an endpoint depends on treatment adjustment. The registry record does not explain how dose changes were governed, making that an important detail for a full assessment of the design and analysis.

The record lists a broad set of secondary measures, from renal function to gastrointestinal symptoms, quality of life, and genotype-stratified symptom changes. Such breadth can help characterize multiple aspects of a trial, but it also raises the importance of prespecifying which comparisons are primary and how multiplicity is addressed. That strategy is not reported in the registry record.

Most importantly, statistical methods can only support conclusions when the relevant outcomes, estimates, and uncertainty are reported. The primary endpoint definition and trial design are available, but the primary comparison is not. The record therefore illustrates the distinction between a well-defined question and evidence sufficient to answer it: the former is stated, while the numerical result required for the latter is not reported in the registry record.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific details needed to interpret the primary comparison are not reported in the registry record. These include the arm-specific primary outcome counts, the estimated treatment contrast, confidence intervals, p-values, and the statistical model or test used. The record also does not give the number of randomized participants included in each primary analysis arm, or a complete participant flow from enrollment through outcome assessment.

The population definition states that participants needed consent, at least one dose, and baseline and post-baseline data sufficient to calculate the endpoint. The description is truncated while specifying the dose data. This limits assessment of how the stated intention-to-treat population was implemented and how participants with missing endpoint information were handled. Missing-data methods and sensitivity analyses are not reported in the registry record.

The endpoint relies on dose steps and dose reduction, but operational definitions, permitted dose-adjustment rules, and assessment procedures are not reported in the registry record. Since masking was none, the absence of detail about who made or assessed dose decisions limits evaluation of possible measurement or performance influences; it does not demonstrate that such influences occurred.

Although 24 outcome measures are listed, no analyses are reported, and multiplicity procedures are not described. The registry record also lacks detailed safety definitions, event relatedness, timing, and a complete account of deaths. These limitations restrict interpretation of both efficacy and safety. They do not establish that the study was conducted improperly; they identify information not reported in the registry record.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study. — NCT01056822.
• Registry record last updated 2014-12-03; status last verified 2014-12.
• Results first posted 2014-12-03.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes a completed Phase 4 randomized, parallel, open-label study sponsored by Novartis Pharmaceuticals, with enrollment of 89. It compares mycophenolate sodium with mycophenolate mofetil in the setting of renal-allograft acute-rejection prophylaxis. The primary endpoint counts participants achieving at least two higher MPA dose steps and reducing tacrolimus dose at 12 months from baseline.

The record lists 24 outcome measures and no analyses. It does not report the primary outcome counts by arm, a comparative effect estimate, uncertainty, or the analysis plan. Safety entries include serious and other adverse event counts and a list of serious adverse event terms, but deaths and event relatedness are not reported in the registry record. The trial question and design can be described, but its primary comparative result cannot be interpreted from the registry record.